PATENT CLAIM ANALYSIS

Application Number: 16131945
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "050000"]

Abstract:
Compositions and methods of using nintedanib for improving the success rate of glaucoma filtration surgery are disclosed herein. Nintedanib can be used alone or in combination with an anti-metabolite drug in a topical or implant eye formulation.

Claim (Index 18):
The method of  claim 13 , wherein nintedanib is in either a semi-solid or solid sustained-release implant is injected into the affected eye.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 97.0
- Lexical Diversity: 1.11429
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15375820', '15474620', '15991382', '15991698', '13800912']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7800017151989447
- 35 USC 102 Novelty (BERT): 0.5131945883983348
- Combined Prediction Score: 0.7533210025188837
- Mean Citation Score: 278.90584
- Max Citation Score: 296.6952
- Similarity Product: 225.3328324513436

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test